Method for finding low abundance sequences by hybridization (FLASH)

US11046995B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11046995-B2
Application numberUS-201716315975-A
CountryUS
Kind codeB2
Filing dateAug 14, 2017
Priority dateAug 16, 2016
Publication dateJun 29, 2021
Grant dateJun 29, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method of sample analysis is provided. In some embodiments, the method comprises: (a) digesting a mixed nucleic acid sample with a plurality of reprogrammed nucleic acid-directed endonucleases that target sequences of interest to produce a digested sample, wherein at least some of the fragments in the digested sample comprise: (i) a sequence of interest and (ii) at least one ligatable end that has been generated by endonuclease cleavage; (b) enriching for fragments that contain the sequence of interest; and (c) analyzing the enriched fragments. Kits for performing the method are also provided.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of sample analysis, comprising: (a) digesting a phosphatase-treated mixed nucleic acid sample with a plurality of reprogrammed nucleic acid-directed endonucleases that target sequences of interest to produce a digested sample, wherein at least some of the fragments in the digested sample comprise: (i) a sequence of interest and (ii) at least one ligatable end that has been generated by endonuclease cleavage; (b) enriching for fragments that contain the sequence of interest; and (c) analyzing the enriched fragments. 2. The method of claim 1 , wherein the method comprises ligating an adaptor to the ligatable ends generated by endonuclease cleavage in step (a). 3. The method of claim 2 , wherein the adaptor comprises capture moiety and the enriching is done by binding the capture moiety to a support, and washing away the unbound nucleic acid. 4. The method of claim 1 , wherein the endonucleases digestion of (a) produces fragments of in a defined size range. 5. The method of claim 4 , wherein the enriching is done by size selecting the fragments. 6. The method of claim 1 , wherein the endonuclease digestion of (a) produces fragments that have ends that are both ligatable. 7. The method of claim 1 , wherein digestion of (a) creates fragments having ligatable endonuclease cleavage sites on both ends, and the method comprises ligating adaptors to both ends of the fragments. 8. The method of claim 7 , wherein the enriching is done by amplifying the ligated fragments using primers that hybridize to the adaptors, or complements thereof. 9. The method of claim 8 , wherein the adaptors contain a molecule indexer. 10. The method of claim 1 , wherein the method comprises ligating indexed adaptors to both ends of the fragments where the index is a series of random nucleotides long enough that there is a high probability of every fragment receiving a distinct index, sequencing the ligated fragments to produce sequence reads, and then counting the number of molecule indexer sequences that are associated with a sequence of interest in the sequence reads, thereby provide an estimate of the copy number of the sequence of interest in the nucleic acid sample. 11. The method of claim 1 , wherein the method comprises: (a) separately digesting: (I) a first portion of the mixed nucleic acid sample with a plurality of reprogrammed nucleic acid-directed endonucleases that target sequences of interest to produce a first digested sample, wherein at least some of the fragments in the digested sample comprise: (i) a first sequence of interest and (ii) at least one ligatable end that has been generated by endonuclease cleavage; (II) a second portion of the mixed nucleic acid sample with a plurality of reprogrammed nucleic acid-directed endonucleases that target sequences of interest to produce a second digested sample, wherein at least some of the fragments in the digested sample comprise: (i) a second sequence of interest and (ii) at least one ligatable end that has been generated by endonuclease cleavage; wherein at least some of the fragments in the first digested sample overlap with at least some of the fragments in the second digested sample; (b) enriching for fragments that contain the sequences of interest; (c) sequencing the enriched sequences to produce a plurality of sequence reads; and (d) assembling overlapping sequence reads, thereby obtaining a contig of a first sequence of interest and a second sequence of interest. 12. The method of claim 1 , wherein the ligatable ends generated by endonuclease treatment are blunt ends. 13. The method of claim 1 , wherein the mixed nucleic acid sample comprises DNA from at least two organisms. 14. The method of claim 13 , wherein the at least two organisms comprise a mammal and a pathogen. 15. The method of claim 14 , wherein the pathogen is a virus, bacteria or fungus. 16. The method of claim 15 , wherein the at least two organisms comprise a mammal and a microbiome. 17. The method of claim 1 , wherein the wherein the mixed sample comprises wild type and mutant DNA. 18. The method of claim 1 , wherein the mixed sample is an environmental sample, a sample from a crime scene or an archaeological sample. 19. The method of claim 1 , wherein the mixed sample is made from a clinical sample. 20. The method of claim 19 , wherein the clinical sample is a bodily fluid or excretion.

Assignees

Inventors

Classifications

  • Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34) · CPC title

  • Ligating adaptors · CPC title

  • Methods for sequencing · CPC title

  • C12N9/22Primary

    Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

  • C12Q1/6806Primary

    Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11046995B2 cover?
A method of sample analysis is provided. In some embodiments, the method comprises: (a) digesting a mixed nucleic acid sample with a plurality of reprogrammed nucleic acid-directed endonucleases that target sequences of interest to produce a digested sample, wherein at least some of the fragments in the digested sample comprise: (i) a sequence of interest and (ii) at least one ligatable end tha…
Who is the assignee on this patent?
Univ California
What technology area does this patent fall under?
Primary CPC classification C12N9/22. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).